Skip to main content
https://pbs.twimg.com/media/FrlgscQX0AE3Vtf.jpg
An exciting year and time for GCA and PMR treatment! - Tocilizumab (IL-6i) - Secukinumab (IL-17i) - Sarilumab (IL-6i) - Mavrilimumab (GM-CSF receptor mAb) - Tofacitinib (JAKinib) @RheumNow #RNL2023 https://t.co/d0T2RAssFY
Robert B Chao, MD
19-03-2023
×